RxDoctor Payments Data

Ashlin Brown, PA

Physician Assistant · Middletown, RINPI 1437729332

Payments from drug & device makers

What this record shows

This record is dominated by food and beverage: $2,226 of the $2,662 with a category attached, or 83.7%. It is spread thinly across 14 manufacturers, the largest accounting for just 19.9% — the pattern of someone who eats at a lot of different presentations. 2025 is the largest year on record at $1,026, more than ten times the $31 reported in 2021.

$2,662in general payments, 2019–2025

Across 93 payments — averaging $28.62 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Regeneron Healthcare Solutions, Inc.$529
  • AbbVie$474
  • Johnson & Johnson$415
  • LEO Pharma Inc.$389
  • Galderma Laboratories, L.p.$260
  • Pfizer$168
  • plus $428 from 8 others

What the payments were for

  • Food & beverage$2,22684%
  • Education$43516%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,662 in reported general payments places this provider in the 85th percentile of 481 physician assistant providers in Rhode Island.

See all physician assistant providers in Rhode Island

Medicare billing

Part B allowed, 2024
$73,394
Medicare patients
239
Services billed
1,291

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Humira(Cf) PenAdalimumab15$241,738
Taltz AutoinjectorIxekizumab12$77,676
OtezlaApremilast11$53,206
Tacrolimus29$4,127
Ketoconazole226$3,169
Clindamycin Phosphate72$3,139
Fluorouracil50$2,972
Clobetasol Propionate69$2,860
Betamethasone Dipropionate47$2,103
Fluocinonide44$1,896
Tretinoin51$1,617
Doxycycline Hyclate53$1,412
Triamcinolone Acetonide117$1,210
Ciclopirox30$765
Metronidazole11$689

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AmgenOtezla$47$53,20611 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 481 physician assistant providers in Rhode Island.

Other physician assistant in Middletown

See the full list for Rhode Island

Where these figures come from

Is this you, or does something look wrong? →